EAST RUTHERFORD, N.J. and RHEINFELDEN, Switzerland, July 6, 2011 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM, “Cambrex”) and Tillotts Pharma AG (“Tillotts”) are pleased to announce they have entered into a Development and Commercialization Agreement for a proprietary mesalamine-based (5-ASA) technology for use in the treatment of Inflammatory Bowel Disease (IBD).
“This deal, which gives Tillotts worldwide access to an exciting proprietary 5-ASA-based technology, is an additional important step in our forceful efforts over the years to come to build an attractive and innovative gastrointestinal product portfolio, complementary to our Asacol® and Colpermin®,” commented Thomas A. Toth von Kisker, President and CEO of Tillotts.
Steven M. Klosk, President and CEO of Cambrex added, “Today’s announcement serves as a prime example of Cambrex’s commitment to accelerating our customers’ drug development processes by providing technology-added products and services and further underscores our goal to being a leading player in the development and supply of mesalamine-based active ingredients.”
Under the terms of the agreement, Tillotts has acquired from Cambrex worldwide exclusive rights to develop and commercialize drug products based on the proprietary 5-ASA-based technology in exchange for developmental, regulatory and IP milestone payments as well as royalties. Cambrex previously acquired the exclusive rights to this technology from PLx Pharma Inc. (Houston, TX).
About Tillotts
Tillotts is a speciality pharma company with a leading position in the field of gastroenterology with its headquarters in Rheinfelden, Switzerland. It is a subsidiary of Zeria Pharmaceutical Co., Ltd., (www.zeria.co.jp) a company publicly traded on the Tokyo stock exchange. Tillotts specializes in the development and commercialization of pharmaceutical products, diagnostics as well as medical devices all in the field of gastroenterology. For more information, please visit www.tillotts.com.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. We offer Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.
Tillotts’ trade marks Asacol®, Octasa®, Asacolon®, Colpermin®, Topasa® and Xenema® are either registered or applied for in up to 70 countries. The trade mark Asacol® is a registered trade mark by Warner Chilcott in the United States of America, Canada and the United Kingdom. Asacol® is a registered trade mark in Italy by Giuliani and in Switzerland by Sanofi-Aventis. In the Benelux the trade mark is registered by Nycomed. Colpermin® is a registered trade mark by Johnson & Johnson for the United Kingdom and Ireland.
SOURCE Cambrex Corporation; Tillotts Pharma AG
